Search
Verastem Inc
VSTMAdd to Watchlist
4.500USD
+0.400+9.76%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
395.29MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+9.76%
5 Days
+19.05%
1 Month
+16.58%
6 Months
-37.76%
Year to Date
-41.71%
1 Year
-6.25%
Key Figures
4.100Open
4.570High
2.97MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
3.38%Turnover Ratio
4.100Prev. Close
4.070Low
9.20MTurnover
LossP/E Static
4.83P/B
0.00%Div Yield TTM
-107.90%ROA
11.24552wk High
1.30Volume Ratio
-130.64MNet Profit
87.84MShares
-2.4328EPS TTM
0.28Beta
-786.15%ROE
4.00052wk Low
12.20%Amplitude
83.66%Gross Margin
395.29MMarket Cap
1.33Reward/Risk
4.67%Risk Rate
TradingKey Stock Score of Verastem Inc
Currency: USD Updated: 2026-07-02Key Insights
Verastem Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 42 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 15.12.In the medium term, the stock price is expected to trend down.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Verastem Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Verastem Inc Highlights
StrengthsRisks
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
Growing
The company is in a growing phase, with the latest annual income totaling USD 30.91M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 30.91M.
Fairly Valued
The company’s latest PE is -1.85, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 83.43M shares, increasing 1.27% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 37.30K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.47.
Analyst Rating
Based on
9
analysts
Buy
Current Rating
15.125
Target Price
+268.90%
Upside Space
Verastem Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Verastem Inc Info
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
Ticker SymbolVSTM
CompanyVerastem Inc
CEOPaterson (Daniel W)
Websitehttps://www.verastem.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Verastem Inc (VSTM)?
The current price of Verastem Inc (VSTM) is 4.50.
What is the symbol of Verastem Inc?
The ticker symbol of Verastem Inc is VSTM.
What is the 52-week high of Verastem Inc?
The 52-week high of Verastem Inc is 11.24.
What is the 52-week low of Verastem Inc?
The 52-week low of Verastem Inc is 4.00.
What is the market capitalization of Verastem Inc?
The market capitalization of Verastem Inc is 395.29M.
Is Verastem Inc (VSTM) currently rated as Buy, Hold, or Sell?
According to analysts, Verastem Inc (VSTM) has an overall rating of Buy, with a price target of 15.12.
What is the Earnings Per Share (EPS TTM) of Verastem Inc (VSTM)?
The Earnings Per Share (EPS TTM) of Verastem Inc (VSTM) is -3.02.